Get the Stockscreener App
6.93
6.45%
0.42
After Hours:
6.91
-0.02
-0.29%
Monte Rosa Therapeutics Inc stock is traded at $6.93, with a volume of 2.62M.
It is up +6.45% in the last 24 hours and down -17.11% over the past month.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
See More
Previous Close:
$6.51
Open:
$6.44
24h Volume:
2.62M
Relative Volume:
1.07
Market Cap:
$425.76M
Revenue:
-
Net Income/Loss:
$-130.41M
P/E Ratio:
-2.6965
EPS:
-2.57
Net Cash Flow:
$-67.76M
1W Performance:
-8.33%
1M Performance:
-17.11%
6M Performance:
+94.66%
1Y Performance:
+28.33%
1-Day Range:
$6.41
$7.14
1-Week Range:
$6.15
$7.9463
52-Week Range:
$3.21
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics Inc
Sector
Industry
Phone
617-949-2643
Address
321 HARRISON AVENUE, BOSTON
Compare GLUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
6.93 | 425.76M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-13-22 | Initiated | UBS | Buy |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
View All
Monte Rosa Therapeutics Inc Stock (GLUE) Latest News
Wells Fargo Downgrades Monte Rosa Therapeutics (GLUE) - MSN
Monte Rosa Therapeutics (NASDAQ:GLUE) Lowered to Equal Weight Rating by Wells Fargo & Company - MarketBeat
The Manufacturers Life Insurance Company Buys 15,168 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - Marketscreener.com
Monte Rosa Therapeutics appoints new board member - Investing.com
Monte Rosa Therapeutics appoints new board member By Investing.com - Investing.com UK
Monte Rosa Therapeutics Strengthens Board with Teva's R&D Chief, Advancing Molecular Glue Platform - StockTitan
Monte Rosa reports promising cancer therapy results By Investing.com - Investing.com Nigeria
Monte Rosa reports promising cancer therapy results - Investing.com
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - The Manila Times
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer - The Manila Times
Monte Rosa Therapeutics Announces Closing of Global License - GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at the - GlobeNewswire
Intech Investment Management LLC Makes New $77,000 Investment in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Up 8.7%Here's What Happened - MarketBeat
Monte Rosa Therapeutics provides development progress on ongoing MRT-2359 study - Yahoo Finance
Monte Rosa Therapeutics (GLUE) Price Target Increased by 5.66% to 16.32 - MSN
Monte Rosa reports favorable MRT-2359 trial results By Investing.com - Investing.com Nigeria
Monte Rosa reports favorable MRT-2359 trial results - Investing.com India
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors - The Manila Times
Monte Rosa's Cancer Drug MRT-2359 Shows Promising Safety Profile in Phase 1/2 Trial - StockTitan
Monte Rosa Therapeutics: A First Assessment (NASDAQ:GLUE) - Seeking Alpha
Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High? - MSN
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference - The Manila Times
Monte Rosa Therapeutics CEO to Present at Piper Sandler Healthcare Conference | GLUE Stock News - StockTitan
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet - MSN
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Growth in Short Interest - MarketBeat
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference - GlobeNewswire
Monte Rosa Therapeutics to Present at Jefferies Healthcare Conference: MGD Innovation Spotlight | GLUE Stock News - StockTitan
FMR LLC Increases Stake in Monte Rosa Therapeutics Inc - GuruFocus.com
News Flash: Analysts Just Made A Sizeable Upgrade To Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Forecasts - Simply Wall St
Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), - Yahoo Finance
Wedbush Equities Analysts Raise Earnings Estimates for GLUE - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Earns “Outperform” Rating from Wedbush - Defense World
Monte Rosa Therapeutics Expands Pipeline with Novartis Deal - TipRanks
Monte Rosa Therapeutics earnings beat by $0.18, revenue topped estimates - Investing.com Canada
Monte Rosa Therapeutics: Q3 Earnings Snapshot - Barchart
Monte Rosa Therapeutics Inc (GLUE) Quarterly 10-Q Report - Quartzy
Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade - MSN
Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice - MSN
Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Monte Rosa Secures $2.1B Novartis Deal, Extends Cash Runway to 2028 in Major Pipeline Win | GLUE Stock News - StockTitan
Equities Analysts Issue Forecasts for GLUE FY2024 Earnings - Defense World
Biogen, Neomorph pact worth $1.45B for molecular glue degraders - BioWorld Online
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):